Recce Pharmaceuticals has completed dosing in its Phase 1/2 UTI/Urosepsis clinical trial. The study evaluated RECCE 327 administered through rapid intravenous infusion.

The trial saw six human subjects receive a 4,000mg dose of R327 over a 20-minute period – the highest dosage to date.

An independent safety committee will review the collected data, with preliminary results expected in the coming weeks.

"We have successfully reached a new milestone in this trial by administering a 4,000mg dose over a fast 20-minute infusion to all subjects, the highest dosage achieved so far in this clinical trial," said CEO James Graham.